UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Presentations
A phase 2 randomized, double-blind, placebo-controlled trial of
radium-223 dichloride with exemestane and everolimus in patients
with HER2-negative hormone receptor-positive breast cancer and
bone metastases.
Authors*: Hope S. Rugo, Rui Li, Oana Petrenciuc, Amily Zhang, Robert E. Coleman
Abstract #: TPS621
Presentation Date/Time: Sunday, June 5: 8:00 - 11:30 AM
Location: Hall A, Poster Board #105a
Poster Session: Breast Cancer - HER2/ER
Citation: J Clin Oncol 34, 2016 (suppl; abstr TPS621)
Rugo Research Interests: Dr. Rugo, Director of Breast Oncology & Clinical Trials Education, is PI on multiple
clinical trials focusing on combining novel targeted therapeutics to improve the treatment of both early & late
stage breast cancer (BC). She also works on studies to improve supportive care for early & late stage BC
patients, including with UCSFs Advanced Breast Cancer Program. Dr. Rugo has numerous collaborations with
large academic medical centers & consortia in order to expand the novel therapies available to patients. She
was the director of the 2016 ASCO Breast Cancer Education Committee meeting, is a member of the Alliance
& is a founding member of the Breast Cancer Research Consortium where she co-leads the triple negative
working group. She is on the novel agents committee for the neoadjuvant multi-center I SPY2 trial. At UCSF,
Dr. Rugo runs the Breast Forum, a bimonthly educational session for breast cancer patients, families & friends
from throughout the bay area.
http://cancer.ucsf.edu/people/profiles/rugo_hope.3648
*UCSF authors in bold
61